KRT9抗体;KRT9 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using KRT9 mouse mAb against HepG2 (1), MCF-7 (2), NIH/3T3 (3), rat heart (4), mouse heart (5), Hela (6), and HUVEC (7) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of Hela cells using KRT9 mouse mAb (green) and negative control (red).    

  
  

The keratin 9 (KRT9) antibody is a tool used to detect the KRT9 protein, a type I intermediate filament protein encoded by the *KRT9* gene. KRT9 is predominantly expressed in the suprabasal layers of palmoplantar epidermis, where it forms heteropolymers with keratin 1 (KRT1) to provide mechanical resilience to skin subjected to high friction. Its tissue-specific expression makes it a critical marker for studying epidermal differentiation and integrity.

Mutations in *KRT9* are linked to epidermolytic palmoplantar keratoderma (EPPK), an autosomal dominant disorder characterized by thick, blistering skin on palms and soles. KRT9 antibodies aid in diagnosing EPPK by identifying abnormal protein aggregation or loss in skin biopsies. These antibodies are also used in research to explore KRT9's role in epithelial pathologies, including cancer. For example, altered KRT9 expression has been observed in squamous cell carcinomas, suggesting potential diagnostic or prognostic relevance.

Available as monoclonal or polyclonal variants, KRT9 antibodies are applied in immunohistochemistry (IHC), Western blotting (WB), and immunofluorescence (IF) to map protein distribution and expression levels. Their specificity and reliability depend on epitope targets and validation in relevant tissues. Continued research with KRT9 antibodies enhances understanding of keratin-related diseases and epidermal biology, supporting therapeutic development for skin disorders.